EA201492292A1 - Препарат антител - Google Patents

Препарат антител

Info

Publication number
EA201492292A1
EA201492292A1 EA201492292A EA201492292A EA201492292A1 EA 201492292 A1 EA201492292 A1 EA 201492292A1 EA 201492292 A EA201492292 A EA 201492292A EA 201492292 A EA201492292 A EA 201492292A EA 201492292 A1 EA201492292 A1 EA 201492292A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
preparation antibodies
sugars
antibodies
surfactant
Prior art date
Application number
EA201492292A
Other languages
English (en)
Other versions
EA033373B1 (ru
Inventor
Марта Косенза
Кристоф Штарк
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48914378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492292(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201492292A1 publication Critical patent/EA201492292A1/ru
Publication of EA033373B1 publication Critical patent/EA033373B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Антитела против BAFFR готовят в виде жидкого лекарственного препарата, включающего активный ингредиент антитело в высокой концентрации, для доставки пациенту без высоких уровней агрегации антитела. Фармацевтическая композиция на водной основе может включать один или более сахаров, буферный агент, поверхностно-активное вещество и/или свободную аминокислоту.
EA201492292A 2012-06-12 2013-06-11 Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему EA033373B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658472P 2012-06-12 2012-06-12
PCT/IB2013/054777 WO2013186700A1 (en) 2012-06-12 2013-06-11 Antibody formulation

Publications (2)

Publication Number Publication Date
EA201492292A1 true EA201492292A1 (ru) 2015-04-30
EA033373B1 EA033373B1 (ru) 2019-10-31

Family

ID=48914378

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492292A EA033373B1 (ru) 2012-06-12 2013-06-11 Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему

Country Status (36)

Country Link
US (4) US9216219B2 (ru)
EP (2) EP2858671B1 (ru)
JP (1) JP6265978B2 (ru)
KR (1) KR102124820B1 (ru)
CN (1) CN104363920B (ru)
AR (1) AR091413A1 (ru)
AU (1) AU2013276112B2 (ru)
BR (1) BR112014030820B1 (ru)
CA (1) CA2875386C (ru)
CL (1) CL2014003370A1 (ru)
CO (1) CO7151487A2 (ru)
CY (1) CY1122181T1 (ru)
DK (1) DK2858671T3 (ru)
EA (1) EA033373B1 (ru)
EC (1) ECSP15017314A (ru)
ES (1) ES2751659T3 (ru)
GT (1) GT201400285A (ru)
HK (1) HK1203146A1 (ru)
HR (1) HRP20191827T1 (ru)
HU (1) HUE045523T2 (ru)
IL (1) IL235966B (ru)
LT (1) LT2858671T (ru)
MA (1) MA37616A1 (ru)
MX (1) MX363380B (ru)
MY (1) MY179818A (ru)
NZ (1) NZ630885A (ru)
PE (1) PE20150200A1 (ru)
PH (1) PH12014502778B1 (ru)
PL (1) PL2858671T3 (ru)
PT (1) PT2858671T (ru)
SG (1) SG11201408174UA (ru)
SI (1) SI2858671T1 (ru)
TN (1) TN2014000488A1 (ru)
TW (1) TWI653983B (ru)
WO (1) WO2013186700A1 (ru)
ZA (1) ZA201408547B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2521568B1 (en) 2010-01-06 2018-07-25 Dyax Corp. Plasma kallikrein binding proteins
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co KALLIKREIN PLASMA BINDING PROTEINS
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
CN105051068A (zh) 2013-03-15 2015-11-11 戴埃克斯有限公司 抗血浆激肽释放酶抗体
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN104730237A (zh) * 2013-12-23 2015-06-24 国家纳米科学中心 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
KR101597037B1 (ko) 2014-06-26 2016-02-24 엘지디스플레이 주식회사 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
CA2979713A1 (en) * 2015-03-30 2016-10-06 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EA201891339A1 (ru) * 2015-12-07 2019-01-31 Мерк Патент Гмбх Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
WO2017104778A1 (ja) * 2015-12-18 2017-06-22 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
AU2017286375B2 (en) * 2016-06-16 2019-04-18 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
MX2019004690A (es) 2016-10-19 2019-09-27 Invenra Inc Constructos de anticuerpos.
JP2020506716A (ja) 2016-12-22 2020-03-05 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
SI3658184T1 (sl) * 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
KR20200044023A (ko) * 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물
SG11202004187UA (en) * 2017-11-29 2020-06-29 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
MX2021007393A (es) * 2018-12-18 2021-09-23 Novartis Ag Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
AU2020227770A1 (en) * 2019-02-26 2021-09-23 Innovent Biologics (Suzhou) Co., Ltd. Preparations containing anti-CD47 antibody, and preparation method and use therefor
EP4055047A1 (en) 2019-11-06 2022-09-14 Novartis AG Treatment for sjögren's syndrome
WO2021136274A1 (zh) * 2019-12-30 2021-07-08 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
EP4094777A4 (en) * 2020-01-21 2024-01-24 Innovent Biologics Suzhou Co Ltd RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
KR20230042594A (ko) 2020-08-04 2023-03-28 노파르티스 아게 B 세포 악성종양의 치료
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
CN117203240A (zh) 2021-05-04 2023-12-08 诺华股份有限公司 使用抗baffr抗体治疗狼疮肾炎
TW202302146A (zh) 2021-05-04 2023-01-16 瑞士商諾華公司 使用抗baffr抗體治療全身性紅斑狼瘡
TW202330604A (zh) * 2021-09-29 2023-08-01 美商蜻蜓醫療公司 靶向ｂａｆｆ—ｒ的抗體及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2375527A1 (en) 1999-06-23 2000-12-28 Oregon Health And Science University Method for enhancing hematopoiesis
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
EP1946776B1 (en) 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0518994A2 (pt) * 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
PE20110563A1 (es) 2008-07-17 2011-08-29 Novartis Ag Anticuerpos antagonistas de baffr
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Also Published As

Publication number Publication date
SI2858671T1 (sl) 2019-11-29
MX363380B (es) 2019-03-21
TW201402144A (zh) 2014-01-16
TWI653983B (zh) 2019-03-21
HK1203146A1 (en) 2015-10-23
BR112014030820B1 (pt) 2023-02-07
AU2013276112A1 (en) 2014-12-18
NZ630885A (en) 2016-01-29
CO7151487A2 (es) 2014-12-29
LT2858671T (lt) 2019-10-25
AR091413A1 (es) 2015-02-04
EA033373B1 (ru) 2019-10-31
WO2013186700A1 (en) 2013-12-19
DK2858671T3 (da) 2019-10-21
GT201400285A (es) 2015-10-15
EP2858671B1 (en) 2019-07-24
TN2014000488A1 (en) 2016-03-30
US20180051092A1 (en) 2018-02-22
CA2875386C (en) 2022-09-13
JP2015521593A (ja) 2015-07-30
ECSP15017314A (es) 2018-06-30
HUE045523T2 (hu) 2020-01-28
EP2858671A1 (en) 2015-04-15
IL235966B (en) 2020-05-31
BR112014030820A2 (pt) 2017-07-25
CN104363920A (zh) 2015-02-18
MX2014015262A (es) 2015-06-23
US20180251564A1 (en) 2018-09-06
PE20150200A1 (es) 2015-02-08
CL2014003370A1 (es) 2015-02-06
PL2858671T3 (pl) 2020-01-31
ES2751659T3 (es) 2020-04-01
US9751951B2 (en) 2017-09-05
CN104363920B (zh) 2018-05-04
IL235966A0 (en) 2015-01-29
JP6265978B2 (ja) 2018-01-24
MA37616A1 (fr) 2017-08-31
PH12014502778A1 (en) 2015-02-02
KR20150029683A (ko) 2015-03-18
PT2858671T (pt) 2019-10-28
US20130344088A1 (en) 2013-12-26
EP3593814A1 (en) 2020-01-15
PH12014502778B1 (en) 2015-02-02
AU2013276112B2 (en) 2015-07-09
US10689451B2 (en) 2020-06-23
US20160145341A1 (en) 2016-05-26
ZA201408547B (en) 2015-12-23
KR102124820B1 (ko) 2020-06-22
US9216219B2 (en) 2015-12-22
SG11201408174UA (en) 2015-01-29
MY179818A (en) 2020-11-16
HRP20191827T1 (hr) 2019-12-27
CA2875386A1 (en) 2013-12-19
CY1122181T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
EA201492292A1 (ru) Препарат антител
TN2014000431A1 (en) Antibody formulatoin
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
WO2012076670A3 (en) Antibody formulation
PH12015502441B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
WO2010100200A3 (en) Lyophilised antibody formulation
EA201491937A1 (ru) Инъецируемая композиция
NZ702342A (en) Pharmaceutical formulation
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
EA201500128A1 (ru) Педиатрические жидкие композиции для перорального введения, содержащие непадутант
TH175929A (th) สูตรตำรับของแอนติบอดี้ (Antibody Formulation)
EA202190637A3 (ru) Пенообразующий препарат и устройство для доставки

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM